공막경유 다이오드레이저 섬모체광응고술이 시력에 미치는 영향 = Change in Visual Acuity Following Trans-Scleral Diode Laser Cyclophotocoagulation in Refractory Glaucoma

국문 초록 (Abstract)

목적: 난치성 녹내장 환자에 시행한 공막경유 다이오드레이저 섬모체광응고술이 시력에 미치는 영향을 알아보고자 하였다.
대상과 방법: 공막경유 다이오드레이저 섬모체광응고술을 시행하고 6개월 이상 추적관찰이 가능했던 148명 148안의 의무기록을 후향 적으로 분석하였으며, 시술 전 시력이 ‘광각 있음’ 이상인 49명(1군)과 ‘광각 없음’이었던 99명(2군)으로 분류하여 섬모체광응고술 후 시력 변화를 포함한 임상결과를 분석하였다.
결과: 평균 추적관찰 기간은 1군은 19.1 ± 13.5개월, 2군은 16.7 ± 12.7개월이었다. 1군과 2군에서 안압( p ＜0.001), 안압하강제의 수( p ＜0.001)는 유의하게 감소하였다. 전체 환자에서 시술 전 최대교정시력은 2.4 ± 0.9 logMAR에서 시술 후 2.5 ± 0.8 logMAR로 유의한 변화는 없었지만( p =0.612), 1군에서는 1.4 ± 1.0 logMAR에서 1.9 ± 1.1 logMAR로 통계적으로 유의하게 감소하였다( p ＜0.001). 1군의 31안(63.3%)에서는 시술 후 0.2 logMAR 이상의 시력저하가 관찰되었고, 이들 중 15안(30.6%)에서는 광각소실이 발생하였다. 전체 환자에서 합병증으로는 각막부종이 5안(3.4%)에서 관찰되었고, 안구로, 만성 저안압이 각각 3안(2.0%), 포도막염이 2안(1.4%)에 서 발생하였다.
결론: 난치성 녹내장 환자에서 공막경유 다이오드레이저 섬모체광응고술은 안압하강 목적으로 유용하게 사용될 수 있지만 시력이 있는 환자에서는 유의한 시력저하를 유발할 수 있다는 점을 염두에 두어야 하겠다.

다국어 초록 (Multilingual Abstract)

Purpose: To evaluate the effects of trans-scleral diode laser cyclophotocoagulation (TSDLC) on best corrected visual acuity (BCVA) in patients with refractory glaucoma.
Methods: The medical records of 148 eyes of 148 patients with refractory glaucoma who were followed-up for over 6 months af-ter TSDLC were analyzed retrospectively. Among them, 49 eyes of 49 subjects who had BCVA greater than no light perception (NLP) before TSDLC were classified as Group 1 and the other 99 eyes of 99 patients who had NLP vision were classified as Group 2. The outcomes of TSDLC including change in BCVA following surgery were analyzed for all patients and 49 subjects.
Results: The mean follow-up period in Group 1 was 19.1 ± 13.5 months and 16.7 ± 12.7 months in Group 2. The intraocular pres-sure (IOP) and the number of IOP lowering medications decreased in both groups (both p < 0.001). In all subjects, there was no significant difference between BCVA before surgery and at the last follow-up (2.4 ± 0.9 log MAR and 2.5 ± 0.8 log MAR, re-spectively, p = 0.612). However, in Group 1, BCVA was decreased from 1.4 ± 1.0 to 1.9 ± 1.1 log MAR after the TSDLC (p < 0.001). In those patients, visual loss ≥ 0.2 log MAR was found in 31 eyes (63.3%) and light perception was lost in 15 eyes (30.6%). After treatment, corneal edema developed in 5 eyes (3.4%), phthisis bulbi and chronic hypotony occurred in 3 eyes each (2%) and iri-docydlitis occurred in 2 eyes (1.4%).
Conclusions: TSDLC in patients with refractory glaucoma showed an efficient reduction in IOP and the number of IOP-lowering medications. However, there was a significant loss in BCVA in many patients and therefore, careful monitoring regarding poten-tial visual loss is necessary when considering TSDLC in glaucoma patients with useful vision.

목차 (Table of Contents)

• 대상과 방법
• 결 과
• 고 찰

참고문헌 (Reference)

1 Bloom PA., "“Cyclodiode”. Trans-scleral diode laser cyclophotocoagulation in the treatment of advanced refractory glaucoma" 104 : 1508-1519, 1997

2 Brindley G., "Value and limitations of cyclocryotherapy" 224 : 545-548, 1986

3 Ishida K., "Update on results and complications of cyclophotocoagulation" 24 : 102-110, 2013

4 Eid TE., "Tube-shunt surgery versus neodymium : YAG cyclophotocoagulation in the management of neovascular glaucoma" 104 : 1692-1700, 1997

5 Panarelli JF., "Transscleral diode laser cyclophotocoagulation after baerveldt glaucoma implant surgery" 23 : 405-409, 2014

6 Rotchford AP., "Transscleral diode laser cycloablation in patients with good vision" 94 : 1180-1183, 2010

7 Nabili S., "Trans-scleral diode laser cyclophoto-coagulation in the treatment of diabetic neovascular glaucoma" 18 : 352-356, 2004

8 Moon IA., "The effect of transscleral diode laser cyclophotocoagulation in refractory glaucoma" 40 : 2252-2258, 1999

9 Bietti G., "Surgical intervention on the ciliary body; new trends for the relief of glaucoma" 142 : 889-897, 1950

10 Ramli N., "Risk factors for hypotony after transscleral diode cyclophotocoagulation" 21 : 169-173, 2012

11 Wilensky JT., "Long-term visual outcome of transscleral laser cyclotherapy in eyes with ambulatory vision" 111 : 1389-1392, 2004

12 Dickens CJ., "Long-term results of noncontact transscleral neodymium : YAG cyclophotocoagulation" 102 : 1777-1781, 1995

13 Han SK., "Long-term results of diode laser trans-scleral cyclophotocoagulation in neovascular glaucoma" 40 : 523-531, 1999

14 Iliev ME., "Long-term outcome of trans-scleral diode laser cyclophotocoagulation in refractory glaucoma" 91 : 1631-1635, 2007

15 Kosoko O., "Long-term outcome of initial ciliary ablation with contact diode laser transscleral cyclophotocoagulation for severe glaucoma. The Diode Laser Ciliary Ablation Study Group" 103 : 1294-1302, 1996

16 Ansari E., "Long-term efficacy and visual acuity following transscleral diode laser photocoagulation in cases of refractory and non-refractory glaucoma" 21 : 936-940, 2007

17 Alward WLM., "Laser surgery in ophthalmology: Practical applications" Appleton and Lange 1992

18 Brancato R., "Histopathology of continuous wave neodymium : yttrium aluminum garnet and diode laser contact transscleral lesions in rabbit ciliary body. A comparative study" 32 : 1586-1592, 1991

19 Hampton C., "Evaluation of a protocol for transscleral neodymium : YAG cyclophotocoagulation in one hundred patients" 97 : 910-917, 1990

20 Francis BA., "Endoscopic ophthalmic surgery of the anterior segment" 59 : 217-231, 2014

21 Ghosh S., "Efficacy of transscleral diode laser cyclophotocoagulation in patients with good visual acuity" 24 : 375-381, 2014

22 Egbert PR., "Diode laser transscleral cyclophotocoagulation as a primary surgical treatment for primary open-angle glaucoma" 119 : 345-350, 2001

23 Noureddin BN., "Diode laser transcleral cyclophotocoagulation for refractory glaucoma : a 1 year follow-up of patients treated using an aggressive protocol" 20 : 329-335, 2006

24 Sood S., "Cyclophotocoagulation versus sequential tube shunt as a secondary intervention following primary tube shunt failure in pediatric glaucoma" 13 : 379-383, 2009

25 Pastor SA., "Cyclophotocoagulation : a report by the American Academy of Ophthalmology" 108 : 2130-2138, 2001

26 Schuman JS., "Contact transscleral continuous wave neodymium : YAG laser cyclophotocoagulation" 97 : 571-580, 1990

27 Schuman JS., "Contact transscleral Nd:YAG laser cyclophotocoagulation. Midterm results" 99 : 1089-1094, 1992

28 Gupta V., "Contact trans-scleral diode laser cyclophotocoagulation treatment for refractory glaucomas in the Indian population" 48 : 295-300, 2000

29 Beckman H., "Carbon dioxide laser scleral dissection and filtering procedure for glaucoma" 88 : 73-77, 1979

30 Murphy CC., "A two centre study of the dose-response relation for transscleral diode laser cyclophotocoagulation in refractory glaucoma" 87 : 1252-1257, 2003

31 Assia EI., "A comparison of neodymium : yttrium aluminum garnet and diode laser transscleral cyclophotocoagulation and cyclocryotherapy" 32 : 2774-2778, 1991

32 Bloom PA., "A comparison between tube surgery, ND : YAG laser and diode laser cyclophotocoagulation in the management of refractory glaucoma" 2013 : 371951-, 2013

33 Yildirim N., "A comparative study between diode laser cyclophotocoagulation and the Ahmed glaucoma valve implant in neovascular glaucoma : a long-term follow-up" 18 : 192-196, 2009

34 Spencer AF., ""Cyclodiode" : results of a standard protocol" 83 : 311-316, 1999